Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Essential hypertensive patients
* If already taking antihypertensive drugs, mean seated diastolic blood pressure (DBP) must be \>=90 and \>=114 mmHg
* If not taking any antihypertensive drugs, mean seated DBP must be \>=95 and \>=114 mmHg
Able to stop all current antihypertensive drugs without risk to the patient based on the investigators opinion.
You may not be if
Patients taking 3 or more antihypertensive drugs at signing the informed consent form
Patients with known or suspected secondary hypertension
Patients with clinically relevant cardiac arrhythmia
Congestive heart failure with New York Heart Association (NYHA) functional class III-IV
Patients with recent cardiovascular events
Patients with a history of stroke or transient ischaemic attack within last 6 months before signing the informed consent form
Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or patients with post-renal transplant or post-nephrectomy
Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with ARBs or ACE inhibitors
Patients with known hypersensitivity to any component of the investigational product, or a known hypersensitivity to dihydropyridine-derived drugs
